Yellow urticaria
Keywords:
UrticariaReferences
Pollack MH, Betof A, Dearden H, Rapazzo K, Valentine I, Brohl AS et al. Safety of resuming anti-PD-1 in patients with immuni-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol. 2018 Jan 1;29(1):250-255.
Combalia A, Fustá X, Guilabert A, Mascaró JM Jr, Estrach T. Hyperbilirubinaemia: the common denominator of yellow urticaria. J Eur Acad Dermatol Venereol. 2017 Dec;31(12):e533.
Published
Issue
Section
License
Copyright (c) 2022 Teresa Maria Kränke, Birger Kränke

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.